# Hsa-miR-99a deficiency contributes to MSI-H colorectal cancer progression by activating the mTOR pathway and inducing Th1/Th2 imbalance

**Authors:** Xuejing Yang, Tingting Zhang, Hu Sun, Huijing Feng, Dong Song

PMC · DOI: 10.3389/fimmu.2026.1796084 · 2026-03-17

## TL;DR

This study shows that low levels of hsa-miR-99a in a type of colorectal cancer called MSI-H lead to cancer progression by affecting the mTOR pathway and changing immune cell activity.

## Contribution

The study identifies hsa-miR-99a as a novel regulator of mTOR signaling and immune imbalance in MSI-H colorectal cancer.

## Key findings

- Hsa-miR-99a is significantly downregulated in MSI-H colorectal cancer compared to MSS tumors.
- Deficiency in hsa-miR-99a correlates with activation of mTOR pathway genes like ATP6V1G2 and WNT6.
- MSI-H tumors show reduced Th1 and increased Th2/Th17 immune infiltration linked to hsa-miR-99a deficiency.

## Abstract

Hsa-miR-99a has been linked to the advancement of several malignancies, including colorectal cancer (CRC). This investigation seeks to elucidate its function and regulatory network in CRC.

Differential expression of hsa-miR-99a was analyzed between microsatellite stable (MSS) and microsatellite instability-high (MSI-H) subgroups. Potential target mRNAs of hsa-miR-99a were retrieved from TargetScan and miRWalk databases. Overlapping mRNAs were subjected to correlation analysis, with candidate genes selected based on |correlation coefficient| > 0.3 and p < 0.05. Enrichment analyses were performed, highlighting key pathways, particularly mTOR signaling. Immune infiltration profiles were compared between MSS and MSI-H groups. Correlation between hsa-miR-99a and mTOR pathway-related genes was validated by RT-qPCR and Western blot. Additionally, multiplex immunohistochemistry (mIHC) with tyramine signal amplification (TSA) was used to characterize the immune microenvironment in MSI-H CRC samples.

Hsa-miR-99a expression was significantly higher in MSS compared to MSI-H groups. Twelve key target genes were identified, including ATP2B2, ATP2B4, SLC8A1, KCNJ5, NTRK3, TNFRSF19, GHR, CXCL12, NTNG1, SDC2, SFRP1, and PRICKLE2. Immune infiltration analysis revealed significant differences in 24 cell types between MSS and MSI-H groups, including Th1, Th2, Th17, and effector memory CD8+ T cells. Ten mTOR pathway-related genes (ATP6V1G2, WNT2, WNT6, WNT9A, WNT9B, FZD1, FZD4, FZD8, IGF1, AKT3) exhibited strong correlation with hsa-miR-99a. Among these, ATP6V1G2 and WNT6 were upregulated in the MSI-H group. mIHC analysis indicated reduced Th1 but increased Th2 and Th17 biomarkers in MSI-H CRC.

This study identified key genes and immune microenvironment alterations regulated by hsa-miR-99a in CRC, offering novel insights and potential therapeutic targets for CRC treatment.

## Linked entities

- **Genes:** ATP2B2 (ATPase plasma membrane Ca2+ transporting 2) [NCBI Gene 491], ATP2B4 (ATPase plasma membrane Ca2+ transporting 4) [NCBI Gene 493], SLC8A1 (solute carrier family 8 member A1) [NCBI Gene 6546], KCNJ5 (potassium inwardly rectifying channel subfamily J member 5) [NCBI Gene 3762], NTRK3 (neurotrophic receptor tyrosine kinase 3) [NCBI Gene 4916], TNFRSF19 (TNF receptor superfamily member 19) [NCBI Gene 55504], GHR (growth hormone receptor) [NCBI Gene 2690], CXCL12 (C-X-C motif chemokine ligand 12) [NCBI Gene 6387], NTNG1 (netrin G1) [NCBI Gene 22854], SDC2 (syndecan 2) [NCBI Gene 6383], SFRP1 (secreted frizzled related protein 1) [NCBI Gene 6422], PRICKLE2 (prickle planar cell polarity protein 2) [NCBI Gene 166336], ATP6V1G2 (ATPase H+ transporting V1 subunit G2) [NCBI Gene 534], WNT2 (Wnt family member 2) [NCBI Gene 7472], WNT6 (Wnt family member 6) [NCBI Gene 7475], WNT9A (Wnt family member 9A) [NCBI Gene 7483], WNT9B (Wnt family member 9B) [NCBI Gene 7484], FZD1 (frizzled class receptor 1) [NCBI Gene 8321], FZD4 (frizzled class receptor 4) [NCBI Gene 8322], FZD8 (frizzled class receptor 8) [NCBI Gene 8325], IGF1 (insulin like growth factor 1) [NCBI Gene 3479], AKT3 (AKT serine/threonine kinase 3) [NCBI Gene 10000]
- **Diseases:** colorectal cancer (MONDO:0005575)

## Full-text entities

- **Genes:** KCNJ5 (potassium inwardly rectifying channel subfamily J member 5) [NCBI Gene 3762] {aka CIR, GIRK4, KATP1, KIR3.4, LQT13}, GHR (growth hormone receptor) [NCBI Gene 2690] {aka GHBP, GHIP}, AKT3 (AKT serine/threonine kinase 3) [NCBI Gene 10000] {aka MPPH, MPPH2, PKB-GAMMA, PKBG, PRKBG, RAC-PK-gamma}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, FZD1 (frizzled class receptor 1) [NCBI Gene 8321], PRICKLE2 (prickle planar cell polarity protein 2) [NCBI Gene 166336] {aka EPM5}, NTRK3 (neurotrophic receptor tyrosine kinase 3) [NCBI Gene 4916] {aka GP145-TrkC, TRKC, gp145(trkC)}, MIR99A (microRNA 99a) [NCBI Gene 407055] {aka MIRN99A, mir-99a}, WNT9A (Wnt family member 9A) [NCBI Gene 7483] {aka WNT14}, FZD8 (frizzled class receptor 8) [NCBI Gene 8325] {aka FZ-8, hFZ8}, ATP2B2 (ATPase plasma membrane Ca2+ transporting 2) [NCBI Gene 491] {aka DFNA82, PMCA2, PMCA2a, PMCA2i}, WNT2 (Wnt family member 2) [NCBI Gene 7472] {aka INT1L1, IRP}, WNT9B (Wnt family member 9B) [NCBI Gene 7484] {aka WNT14B, WNT15}, TNFRSF19 (TNF receptor superfamily member 19) [NCBI Gene 55504] {aka TAJ, TAJ-alpha, TRADE, TROY}, FZD4 (frizzled class receptor 4) [NCBI Gene 8322] {aka CD344, EVR1, FEVR, FZD4S, Fz-4, Fz4}, ATP6V1G2 (ATPase H+ transporting V1 subunit G2) [NCBI Gene 534] {aka ATP6G, ATP6G2, NG38, VMA10}, SLC8A1 (solute carrier family 8 member A1) [NCBI Gene 6546] {aka NCX1}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, SFRP1 (secreted frizzled related protein 1) [NCBI Gene 6422] {aka FRP, FRP-1, FRP1, FrzA, SARP2}, WNT6 (Wnt family member 6) [NCBI Gene 7475], NTNG1 (netrin G1) [NCBI Gene 22854] {aka Lmnt1, NetG1, NetrinG1}, ATP2B4 (ATPase plasma membrane Ca2+ transporting 4) [NCBI Gene 493] {aka ATP2B2, MXRA1, PMCA4, PMCA4b, PMCA4x}, CXCL12 (C-X-C motif chemokine ligand 12) [NCBI Gene 6387] {aka IRH, PBSF, SCYB12, SDF1, TLSF, TPAR1}, SDC2 (syndecan 2) [NCBI Gene 6383] {aka CD362, HSPG, HSPG1, SYND2}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}
- **Diseases:** CRC (MESH:D015179), malignancies (MESH:D009369)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13036217/full.md

---
Source: https://tomesphere.com/paper/PMC13036217